NEW YORK, Dec. 15 Reportlinker.com announces that a new market research report is available in its catalogue:
Big Pharma Performance Before, During and Beyond the Global Recession
Advertisement
http://www.reportlinker.com/p0168549/Big-Pharma-Performance-Before-During-and-Beyond-the-Global-Recession.html
Introduction
This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the recent global recession. It places the pharma sector in the context of other major industry sectors and analyzes the internal dynamics behind pharmaceutical companies' performance.
Advertisement
Scope
*Cross-sector sales analysis before, during and beyond the global recession
*Assessment of high- and low-growth sectors of the prescription pharmaceuticals market
*Discussion of pharma's possible responses to slowing pharma sales growth rates
*Ranking of the top 15 pharma companies over 2005 to 2014
Highlights
The pharma landscape is being reshaped by expiries. This trend has already begun with expiries wiping -3.7 percentage points off the sector's 200508 sales growth rate, turning pharma into one of the slower-growing industry sectors.
The recession has provided some respite for pharma, giving it a stock market boost as it lived up to its defensive reputation and stood as the only sector to achieve positive sales growth. Nevertheless, this only masked the continual expiry-driven decline of pharma sales growth rates.
Between 2009 and 2014, the expiry burden will reach a tipping point, sending year-on-year pharma sales growth rates negative in 2012 and 2013. If pharma is to avoid a continuation of the 200508 stock market revaluation of its worth, it must take action.
Reasons to Purchase
*Assess pharma's sales and stock market performance in relation to other major industry sectors
*Evaluate the strategic shifts within the prescription pharmaceutical market and identify the high- and low-growth sectors of the industry
*Quantify the historical and forecast impact of generics on pharma's sales growth rate
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 Introduction 3
Structure: past, present and future analysis 3
Cross-sector analysis 4
Pharma analysis 6
Data sources 7
Ex-pharma data 7
Pharma data 7
PharmaVitae Explorer database 7
Re-creating analysis from this report using PharmaVitae Explorer queries 7
Further reading 8
Methodology 8
Chapter 2 Executive summary 9
Key findings 9
Insulated from the wider economy, pharma recorded the highest growth of any sector during the recession, but this masked the continuing decline of sales growth rates as expiries take their toll 10
Expiries will shape pharma's corporate landscape... 13
...as the division between high- and low-growth molecule type/therapy area sectors widens 15
Pharma must reposition, diversify and cut costs to maintain stock market performance... 17
Reposition: licensing, restructuring and acquisitions improve biologics, vaccines and rest of world presence 18
Diversify: acquisitions build presence in other sectors 20
Cut costs: restructuring and using acquisitions to achieve economies of scale 22
...or ready itself to a return to the historic trend of market underperformance 23
Company rankings, 2005-08, Q208-Q209, 2009-14 and post-M&A 2009-14 25
TABLE OF CONTENTS 27
TABLE OF FIGURES 27
Chapter 3 Pharma Past - Pre-Recession Analysis, 2005-08 28
Key findings 28
Cross-sector analysis 29
Pharma's growth rate has fallen from double-digit figures to below the cross-sector average 29
Leading up to the recession, pharma has underperformed the S&P 500 30
Expiries have already begun to take their toll on pharma 31
In an expiry-less world, pharma's 2005-08 sales CAGR would have stood at 10.2% 32
Pharma analysis 33
The uneven burden of expiries determines company-by-company performances 33
Combining molecule type with therapy area identifies high- and slowing-growth areas of the industry... 34
...and goes some way to explaining different company performances 35
Exchange rates have helped dollar-reporting pharma companies' performance 37
Acquisitions have driven some companies' sales growth 38
Adjusting for exchange rate fluctuations and M&A alters the pharma landscape 39
Company rankings 40
Chapter 4 Pharma Present - Recession Analysis, Q208-Q209 41
Key findings 41
Cross-sector analysis 42
Pharma was the only sector to record positive sales growth during the worst of the recession 42
Correspondingly, it has outperformed the wider stock market... 43
However, within pharma's bubble, the narrative of expiries eroding year-on-year sales growth rates continues 44
...in an expiry-less world, its performance relative to other sectors would have been even more impressive 45
Pharma analysis 46
Expiries have continued to shape company performances 46
A significant strengthening of the dollar has benefitted euro- and sterling-reporting companies... 47
There has been relatively little completed M&A activity 48
Company rankings 49
Chapter 5 Pharma Future - Post-Recession Analysis, 2009-14 50
Key findings 50
Pharma analysis 51
The patent cliff will drag year-on-year growth into negative territory during 2012 and 2013, before recovering to positive, if marginal, growth in 2014 51
Dragged down by expiries, six companies are forecast negative 2009-14 growth 53
The benefits of being in a 'high-growth' sector are significant 54
Company rankings 56
Pharma must resort to rest of world expansion, diversification, cost-cutting and M&A to bolster its performance 58
Move out of low-growth commoditized markets and into high-growth biologics and vaccines 59
With traditional markets slowing, rest of world expansion looks attractive 60
Contributions from ex-Pharma business units can come at a cost 61
Cost-cutting will make a significant contribution to operating profit growth 62
Mergers can contribute sales growth, cost-cutting opportunities and diversification 63
Except in the event of a double-dip recession, pharma is expected to return to underperforming the market 64
Chapter 6 Appendix 65
Cross-sector data 65
Supporting data 66
Methodology 69
Expiry-less growth rates 69
M&A adjustment 69
Exchange rate adjustment 70
Molecule type by therapy area market segmentation 70
References 71
News articles 71
Data sources 71
Abbreviations 71
Exchange rates 72
About Datamonitor 73
About Datamonitor Healthcare 73
Datamonitor consulting 73
Disclaimer 75
LIST OF TABLES
Table 1: Cross-sector coverage 4
Table 2: Pharma sector coverage 6
Table 3: Pharma sales by lifecycle stage ($bn), 2009-14 11
Table 4: Pharma company sales growth ($m) by lifecycle stage, 2009-14 14
Table 5: Pharma company rankings, prescription pharmaceutical sales ($m), 2005-08 40
Table 6: Pharma company rankings, prescription pharmaceutical sales ($m), Q208-Q209 49
Table 7: Blockbuster product* patent expiries, 2009-14 52
Table 8: Pharma company rankings, prescription pharmaceutical sales ($m), 2009-14 56
Table 9: Post-M&A pharma company rankings, prescription pharmaceutical sales ($m), 2009-14 57
Table 10: Sector sales ($bn), 2005-08 65
Table 11: Sector sales ($bn), Q208-Q209 65
Table 12: Lipitor sales forecast ($m), unadjusted and expiry-less, 2008-09 69
Table 13: Bayer sales ($m), with and without M&A, 2005-08 69
Table 14: Sales growth ($bn) by molecule type vs. therapy area segment, 2002-05 70
Table 15: Sales growth ($bn) by molecule type vs. therapy area segment, 2005-08 70
Table 16: Sales growth ($bn) by molecule type vs. therapy area segment, 2009-14 70
Table 17: Exchange rates, 2009 72
List of Figures
Figure 1: Seasonally-adjusted US GDP growth rate, at annual rates (%), Q105-Q309 3
Figure 2: The PharmaVitae Explorer 7
Figure 3: Pharma market capitalization vs. S&P 500 (rebased), July 2005 to September 2009 10
Figure 4: Pharma sales growth rate (unadjusted and expiry-less) vs. the cross-sector average (%), 2005-14 11
Figure 5: Pharma sales growth by lifecycle stage ($bn), 2009-14 12
Figure 6: Company sales growth by lifecycle stage, percentage of 2009 sales (%), 2009-14 13
Figure 7: Molecule type vs. therapy area sector growth map, 2009-14 15
Figure 8: Strategic focus and growth rate by company, 2009-14 16
Figure 9: Strategic responses to falling sales and operating profit growth 17
Figure 10: Effects of acquisitions on Pfizer, Merck & Co. and Abbott's strategic focus and growth rate by company, 2009-14 18
Figure 11: Abbott-Solvay growth by geography (% of 2009 combined sales), 2009-14 19
Figure 12: Company growth rates, CAGR (%), prescription pharmaceuticals vs. other business units, 2009-14 20
Figure 13: Pfizer-Wyeth growth by business unit (% of 2009 combined sales), 2009-14 21
Figure 14: Operating profit growth ($bn), sales vs. operating margin, 2009-14 22
Figure 15: Pharma market capitalization vs. S&P 500 (rebased), July 2009 to September 2009 23
Figure 16: Company rankings by prescription pharmaceutical sales, 2005-08, Q208-Q209, 2009-14 and post-M&A 2009-14 25
Figure 17: Sector-by-sector sales growth rate, CAGR (%), 2005-08 29
Figure 18: Market capitalization growth rate (%), pharma vs. S&P 500, 2005-08 30
Figure 19: Pharma sales growth rate (%), reported and expiry-less, 2005-08 31
Figure 20: Sector-by-sector sales growth rate, CAGR (%), pharma unadjusted and expiry-less, 2005-08 32
Figure 21: Company sales performance by lifecycle stage, percent of 2005 annual sales (%),2005-08 33
Figure 22: Molecule type vs. therapy area sector growth map, 2005-08 34
Figure 23: Companies on the molecule type vs. therapy area sector growth map, 2005-08 35
Figure 24: Company sales growth rate, CAGR (%), 2005-08 36
Figure 25: USD vs. EUR, GBP, CHF and JPY (rebased), 2005 to H1 2008 37
Figure 26: Company growth rates, CAGR (%), adjusted for exchange rates and M&A, 2005-08 38
Figure 27: Strategic focus and growth rate (XR- and M&A-adjusted) by company, 2005-08 39
Figure 28: Sector sales growth (%), Q208-Q209 42
Figure 29: Pharma market capitalization vs. S&P 500 (rebased), Q208-Q209 43
Figure 30: Pharma sales growth rate (%), reported and expiry-less, 2005-Q209 44
Figure 31: Sector sales growth (%), pharma unadjusted and expiry-less, Q208-Q209 45
Figure 32: Company growth by lifecycle stage, percentage of 2008 sales (%), 2008-09 46
Figure 33: USD vs. EUR, GBP, CHF and JPY (rebased), Q208-Q209 47
Figure 34: Company sales growth, CAGR (%), exchange rate- and M&A-adjusted, Q208-Q209 48
Figure 35: Pharma sales growth rate (%), reported and expiry-less, 2009-14 51
Figure 36: Company growth by lifecycle stage, percentage of 2009 sales (%), 2009-14 53
Figure 37: Molecule type vs. therapy area sector growth map, 2009-14 54
Figure 38: Strategic focus and growth rate by company, 2009-14 55
Figure 39: Company growth rates, CAGR (%), 2009-14 58
Figure 40: Effects of acquisitions on Pfizer, Merck & Co. and Abbott's strategic focus and growth rate by company, 2009-14 59
Figure 41: Seven major market (7MM) sales vs. rest of world (RoW) ($m), 2005-14 60
Figure 42: Company growth rates, CAGR (%), prescription pharmaceuticals vs. other business units, 2009-14 61
Figure 43: Operating profit growth ($bn), sales vs. operating margin, 2009-14 62
Figure 44: Merger growth rates, CAGR (%), PFE-WYE, MRK-SGP and ABT-SOLV, 2009-14 63
Figure 45: Pharma market capitalization vs. S&P 500 (rebased), July 2009 to September 2009 64
Figure 46: Chicago Board Options Exchange's volatility index, 2005-09 66
Figure 47: Trade-weighted dollar index, 2002-09 67
Figure 48: Crude oil price*, dollars per barrel, 2001-09 68
To order this report:
Pharmaceutical Industry: Big Pharma Performance Before, During and Beyond the Global Recession
More Market Research Report
Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
